NS-2664 (LS-193,048) is an
anxiolytic drug with a novel chemical structure, developed by the small pharmaceutical company
NeuroSearch. It has similar effects to
benzodiazepine drugs, but is structurally distinct and so is classed as a
nonbenzodiazepine anxiolytic. NS-2664 is a potent but non-selective
partial agonist at
GABAA receptors, although with little efficacy at the α1 subtype and more at α2 and α3. It has potent
anticonvulsant effects in animal studies, but a relatively short duration of action, and produces little
sedative effects or physical dependence.[1]
References
^Mirza NR, Nielsen EØ (March 2006). "Do subtype-selective gamma-aminobutyric acid A receptor modulators have a reduced propensity to induce physical dependence in mice?". The Journal of Pharmacology and Experimental Therapeutics. 316 (3): 1378–85.
doi:
10.1124/jpet.105.094474.
PMID16352707.
S2CID22700422.